<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110960">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903265</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-CY-F202</org_study_id>
    <nct_id>NCT01903265</nct_id>
  </id_info>
  <brief_title>BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)</brief_title>
  <acronym>BESTFIT</acronym>
  <official_title>A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime has
      shown promise as a treatment of fibromyalgia, but the drug required new formulation
      technology for bedtime use. The present trial is designed to assess the safety and efficacy
      of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Average perceived pain</measure>
    <time_frame>Weeks 12 mean change of perceived average pain intensity from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of TNX-102 (low-dose cyclobenzaprine) sublingual (SL) tablets taken at bedtime over 12 weeks of treatment using an 11-point (0-10) numerical rating scale (NRS) to assess average daily pain over 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change</measure>
    <time_frame>Weeks 2, 4, 8 and 12 or early termination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire</measure>
    <time_frame>Baseline and weeks 2, 4, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient pain improvement response rate</measure>
    <time_frame>Weekly</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Physical Component score</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of TNX-102 SL Tablets</measure>
    <time_frame>Continuously throughout the treatment period (total duration: about 3 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Every adverse events occurring during the study period will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>TNX-102 SL 2.8 mg Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-102 SL 2.8mg Tablets</intervention_name>
    <description>Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.</description>
    <arm_group_label>TNX-102 SL 2.8 mg Tablets</arm_group_label>
    <other_name>Low dose cyclobenzaprine sublingual tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo sublingual tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Primary Fibromyalgia (ACR criteria)

          -  Male or female 18-65 years old

          -  For patients with major depressive disorders only: clinically stable, no suicidal
             risk and stable anti-depressent therapy

          -  Willing and able to withdraw specific therapies (ask PI)

          -  Medically acceptable form of contraception (female only)

          -  Signed informed consent

        Exclusion Criteria:

          -  Arthritis, lupus and other systemic auto-immune diseases

          -  Regional or persistent pain that could interfere with assessment of fibromyalgia pain

          -  Bipolar and psychotic disorders

          -  Increase risk of suicide

          -  Significant clinical (cardiac, systemic infection, systemic corticosteroid
             requirement, drug/alcohol abuse) or laboratory abnormalities.

          -  Unability to wash-out specific medications (ask PI)

          -  Known hypersensitivity to cyclobenzaprine

          -  Others: seizure disorders, sleep apnea, CPAP use, BMI&gt;40
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Schmal</last_name>
    <role>Study Director</role>
    <affiliation>Premier Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel J. Clauw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ann Harbor, MI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>16176 Cortez Boulevard</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>100 West Gore Street</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71 Thomas Johnson Drive</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>370 Faunce Corner Road</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC of Jackson, LLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275 Olentangy River Road</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18660 Bagley Road</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1001 South Market Street</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>322 Memorial Drive</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>601 Broadway</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>sleep</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclobenzaprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
